SCHEMBL197230

SCHEMBL197230

O=C(O)C1CC(C2CCCCC2)CN1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
ALOX15 P16050 1/20 0.50
CYP2C19 P33261 1/20 0.50
SLC1A3 P43003 1/20 0.50
SLC1A2 P43004 1/20 0.50
SLC1A1 P43005 1/20 0.50
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
GRIK1 P39086 4/20 0.43
GRIA1 P42261 3/20 0.43
GRIA2 P42262 3/20 0.43
GRIA3 P42263 3/20 0.43
GRIA4 P48058 3/20 0.43
GRIK2 Q13002 1/20 0.43
GRIK3 Q13003 1/20 0.43
GRIK4 Q16099 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2238814 1.00 DPP4 (0.50) DPP4CYP1A2CYP2D6ALOX15CYP2C19
SCHEMBL7876588 1.00 DPP4 (0.50) DPP4CYP1A2CYP2D6ALOX15CYP2C19
SCHEMBL197231 1.00 DPP4 (0.50) DPP4CYP1A2CYP2D6ALOX15CYP2C19
SCHEMBL7873502 1.00 DPP4 (0.50) DPP4CYP1A2CYP2D6ALOX15CYP2C19
SCHEMBL7876596 1.00 DPP4 (0.50) DPP4CYP1A2CYP2D6ALOX15CYP2C19
SCHEMBL29035113 1.00 DPP4 (0.50) DPP4CYP1A2CYP2D6ALOX15CYP2C19
Hydrochloric Acid SCHEMBL3418559 0.98 DPP4 (0.49) DPP4CYP1A2CYP2D6ALOX15CYP2C19
Hydrochloric Acid SCHEMBL7383848 0.98 DPP4 (0.49) DPP4CYP1A2CYP2D6ALOX15CYP2C19
Hydrochloric Acid SCHEMBL18103704 0.98 DPP4 (0.49) DPP4CYP1A2CYP2D6ALOX15CYP2C19
Hydrochloric Acid SCHEMBL3418556 0.98 DPP4 (0.49) DPP4CYP1A2CYP2D6ALOX15CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026105126-A1 DNA-BASED MECHANOSENSITIVE DELIVERY AGENTS AND USES THEREOF TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2026-05-21 WO claimed
US-20260115253-A1 VISCOUS COMPOSITION FOR TREATING ISCHEMIA UNIV NAT CHENG KUNG (TW) 2026-04-30 US claimed
US-20250051384-A1 NEUTRAL GLYCOSYLATED AMIDES AND DIANIONIC GLUCURONIDATED ACIDS AS STABILIZERS FOR BIOLOGICAL MOLECULES EXTREMOCHEM, LDA. (PT) 2025-02-13 US claimed
CN-118973593-A Novel method for decellularizing extracellular matrix 瑞根克斯科学股份有限公司 2024-11-15 CN claimed
CN-113271960-B Dry powder inhalation formulations and their use for treating lung 布鲁塞尔自由大学 2024-11-05 CN claimed
US-12098162-B2 Neutral glycosylated amides and dianionic glucuronidated acids as stabilizers for biological molecules EXTREMOCHEM, LDA (PT) 2024-09-24 US claimed
CN-117295489-A Compositions, devices and methods for treating respiratory disorders 呼吸解决方案股份有限公司 2023-12-26 CN claimed
CN-116782865-A Atomic layer deposition coated pharmaceutical packages, improved syringes and vials, e.g., for lyophilization/cold chain drugs/vaccines SIO2医药产品公司 2023-09-19 CN claimed
CN-116406377-A anti-NOTCH 2 antibodies and methods of use thereof 基因泰克公司 2023-07-07 CN claimed
CN-115786458-A Genome DNA methylated fragment targeted enrichment and sequencing method 河南大学 2023-03-14 CN claimed
CN-101462996-B Preparation of 4-cyclohexyl proline derivative SHANGHAI INST PHARM INDUSTRY 2011-04-20 CN claimed
US-7884074-B2 Compounds and methods for prevention and/or treatment of inflammation using the same Ikaria Development Subsidiary Two, LLC (US) 2011-02-08 US claimed
EP-2274328-A1 PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION Fibrex Medical Research & Development GmbH (AT) 2011-01-19 EP claimed
US-20100099602-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2010-04-22 US claimed
WO-2010043972-A2 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2010-04-22 WO claimed
WO-2010034041-A1 PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2010-04-01 WO claimed
US-20100081787-A1 PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2010-04-01 US claimed
US-20090286739-A1 PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2009-11-19 US claimed
WO-2009137850-A1 PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2009-11-19 WO claimed
CN-101462996-A Preparation of 4-cyclohexyl proline derivative SHANGHAI INST PHARM INDUSTRY (CN) 2009-06-24 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12098162-B2 Neutral glycosylated amides and dianionic glucuronidated acids as stabilizers for biological molecules FUT6, GUSB, UGGT1 DPP4 366/4885CYP1A2 2169/4885CYP2D6 233/4885
US-20100099602-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY HIF1AN, HIF1A, EGLN3 DPP4 975/4885CYP1A2 2264/4885CYP2D6 2872/4885
US-20260115253-A1 VISCOUS COMPOSITION FOR TREATING ISCHEMIA SERPINE1, CD44, SERPINB8 DPP4 3831/4885CYP1A2 3798/4885CYP2D6 4525/4885
US-20100081787-A1 PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION NGLY1, GHRHR, GHSR DPP4 3514/4885CYP1A2 2694/4885CYP2D6 3352/4885
US-20250051384-A1 NEUTRAL GLYCOSYLATED AMIDES AND DIANIONIC GLUCURONIDATED ACIDS AS STABILIZERS FOR BIOLOGICAL MOLECULES FUT6, GUSB, UGGT1 DPP4 366/4885CYP1A2 2169/4885CYP2D6 233/4885
US-20090286739-A1 PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION NPR3, RXFP3, RXFP1 DPP4 2036/4885CYP1A2 2247/4885CYP2D6 2251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.